Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years ( n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0.5–0.8 mg/kg for ≤12 cycles. With a median (range) follow-up of 60 months (0.1–66), progression-free survival (PFS) and overall survival (OS) benefits for ibrutinib versus chlorambucil were sustained (PFS estimates at 5 years: 70% vs 12%; HR [95% CI]: 0.146 [0.098–0.218]; OS estimates at 5 years: 83% vs 68%; HR [95% CI]: 0.450 [0.266–0.761]). Ibrutinib benefit was also consistent in patients with high prognostic risk ( TP53 mutation, 11q deletion, and/or unmutated IGHV ) (PFS: HR [95% CI]: 0.083 [0.047–0.145]; OS: HR [95% CI]: 0.366 [0.181–0.736]). Investigator-assessed overall response rate was 92% with ibrutinib (complete response, 30%; 11% at primary analysis). Common grade ≥3 adverse events (AEs) included neutropenia (13%), pneumonia (12%), hypertension (8%), anemia (7%), and hyponatremia (6%); occurrence of most events as well as discontinuations due to AEs decreased over time. Fifty-eight percent of patients continue to receive ibrutinib. Single-agent ibrutinib demonstrated sustained PFS and OS benefit versus chlorambucil and increased depth of response over time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-093906 · Cited by 3,787
Self-citationIbrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,639
Self-citationIbrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Bartlett, N. L., Li, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509388 · Cited by 1,583
Self-citationObinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., de la Serna, J., Dilhuydy, M.-S., Illmer, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313984 · Cited by 1,518
Self-citationIbrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
Woyach, J. A., Ruppert, A. S., Heerema, N. A., Zhao, W., Booth, A. M., Ding, W., Bartlett, N. L., Brander, D. M., Barr, P. M., Rogers, K. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1812836 · Cited by 962
Self-citationEstimation of minimally important differences in EQ-5D utility and VAS scores in cancer
Pickard, A. S., Neary, M. P., & Cella, D. (2007) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-5-70 · Cited by 929
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Harrington, B., O’Brien, S., Jones, J. A., Schuh, A., Devereux, S., Chaves, J., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 897
Self-citationByrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., et al. (2015) · Blood · doi:10.1182/blood-2014-10-606038 · Cited by 663
Self-citationEichhorst, B., Fink, A.-M., Bahlo, J., Busch, R., Kovacs, G., Maurer, C., Lange, E., Köppler, H., Kiehl, M., Sökler, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30051-1 · Cited by 627
Moreno, C., Greil, R., Demirkan, F., Tedeschi, A., Anz, B., Larratt, L., Simkovic, M., Samoilova, O., Novak, J., Ben-Yehuda, D., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30788-5 · Cited by 556
Self-citationThompson, P. A., Tam, C. S., O’Brien, S. M., Wierda, W. G., Stingo, F., Plunkett, W., Smith, S. C., Kantarjian, H. M., Freireich, E. J., & Keating, M. J. (2016) · Blood · doi:10.1182/blood-2015-09-667675 · Cited by 505
Mato, A. R., Nabhan, C., Thompson, M. C., Lamanna, N., Brander, D. M., Hill, B., Howlett, C., Skarbnik, A., Cheson, B. D., Zent, C., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.182907 · Cited by 456
Self-citationWang, M. L., Blum, K. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2015) · Blood · doi:10.1182/blood-2015-03-635326 · Cited by 410
O’Brien, S., Furman, R. R., Coutre, S., Flinn, I. W., Burger, J. A., Blum, K., Sharman, J., Wierda, W., Jones, J., Zhao, W., et al. (2018) · Blood · doi:10.1182/blood-2017-10-810044 · Cited by 385
Self-citationEichhorst, B. F., Busch, R., Stilgenbauer, S., Stauch, M., Bergmann, M. A., Ritgen, M., Kranzhöfer, N., Rohrberg, R., Söling, U., Burkhard, O., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206185 · Cited by 333
Management of adverse events associated with idelalisib treatment: expert panel opinion
Coutré, S. E., Barrientos, J. C., Brown, J. R., de Vos, S., Furman, R. R., Keating, M. J., Li, D., O’Brien, S. M., Pagel, J. M., Poleski, M. H., et al. (2015) · Leukemia & Lymphoma · doi:10.3109/10428194.2015.1022770 · Cited by 273
Brown, J. R., Moslehi, J., O’Brien, S., Ghia, P., Hillmen, P., Cymbalista, F., Shanafelt, T. D., Fraser, G., Rule, S., Kipps, T. J., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.171041 · Cited by 267
Self-citationBrown, J. R., Hillmen, P., O’Brien, S., Barrientos, J. C., Reddy, N. M., Coutre, S. E., Tam, C. S., Mulligan, S. P., Jaeger, U., Barr, P. M., et al. (2018) · Leukemia · doi:10.1038/leu.2017.175 · Cited by 243
Self-citationMato, A. R., Hill, B. T., Lamanna, N., Barr, P. M., Ujjani, C. S., Brander, D. M., Howlett, C., Skarbnik, A. P., Cheson, B. D., Zent, C. S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx031 · Cited by 229
Self-citationBurger, J. A., Sivina, M., Jain, N., Kim, E., Kadia, T., Estrov, Z., Nogueras-Gonzalez, G. M., Huang, X., Jorgensen, J., Li, J., et al. (2019) · Blood · doi:10.1182/blood-2018-10-879429 · Cited by 217
Self-citationEvolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy
Burger, J. A., & O'Brien, S. M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0037-8 · Cited by 151
Self-citationBarr, P. M., Robak, T., Owen, C., Tedeschi, A., Bairey, O., Bartlett, N. L., Burger, J. A., Hillmen, P., Coutre, S. E., Devereux, S., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.192328 · Cited by 143
Self-citationQuality of life in chronic lymphocytic leukemia: an international survey of 1482 patients
Shanafelt, T. D., Bowen, D., Venkat, C., Slager, S. L., Zent, C. S., Kay, N. E., Reinalda, M., Sloan, J. A., & Call, T. G. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06791.x · Cited by 140
Long‐term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib
Jain, P., Thompson, P. A., Keating, M. J., Estrov, Z. E., Ferrajoli, A., Jain, N., Kantarjian, H. M., Burger, J. A., O'Brien, S. M., & Wierda, W. G. (2017) · Cancer · doi:10.1002/cncr.30596 · Cited by 122
Self-citationFraser, G. A. M., Cramer, P., Demırkan, F., da Silva, R. S. A., Grosicki, S., Pristupa, A. S., Janssens, A. M., Mayer, J., Bartlett, N. L., Dilhuydy, M. S., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0276-9 · Cited by 119
Self-citationJones, J. A., Hillmen, P., Coutre, S. E., Tam, C. S. L., Furman, R. R., Barr, P. M., Schuster, S. J., Kipps, T. J., Flinn, I. W., Jaeger, U., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14660 · Cited by 76
Self-citationOutcomes of front‐line ibrutinib treated CLL patients excluded from landmark clinical trial
Mato, A. R., Roeker, L. E., Allan, J. N., Pagel, J. M., Brander, D. M., Hill, B. T., Cheson, B. D., Furman, R. R., Lamanna, N., Tam, C. S. L., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25261 · Cited by 70
Self-citationPrognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation
Buccheri, V., Barreto, W. G., Fogliatto, L., Capra, M., Marchiani, M., & Rocha, V. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3503-6 · Cited by 57
Walter, H. S., Jayne, S., Rule, S. A., Cartron, G., Morschhauser, F., Macip, S., Karlin, L., Jones, C. H., Herbaux, C., Quittet, P., et al. (2017) · Blood · doi:10.1182/blood-2017-02-765115 · Cited by 53
Robak, T., Burger, J. A., Tedeschi, A., Barr, P. M., Owen, C., Bairey, O., Hillmen, P., Simpson, D., Grosicki, S., Devereux, S., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25259 · Cited by 26
Self-citationCoutre, S. E., Tedeschi, A., Robak, T., Barr, P. M., Owen, C., Bairey, O., Burger, J. A., Zhou, C., Styles, L. A., James, D. F., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.175380 · Cited by 6
Self-citation
Cited by
Byrd, J. C., Hillmen, P., Ghia, P., Kater, A. P., Chanan-Khan, A., Furman, R. R., O'Brien, S., Yenerel, M. N., Illés, A., Kay, N., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01210 · Cited by 669
Self-citationBarr, P. M., Owen, C., Robak, T., Tedeschi, A., Bairey, O., Burger, J. A., Hillmen, P., Coutre, S. E., Dearden, C., Grosicki, S., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006434 · Cited by 282
Self-citationComparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
Estupiñán, H. Y., Berglöf, A., Zain, R., & Smith, C. I. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.630942 · Cited by 267
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
Wen, T., Wang, J., Shi, Y., Qian, H., & Liu, P. (2021) · Leukemia · doi:10.1038/s41375-020-01072-6 · Cited by 262
Nakhoda, S., Vistarop, A., & Wang, Y. L. (2023) · British Journal of Haematology · doi:10.1111/bjh.18418 · Cited by 104
Metadata
- Authors
- Burger, J. A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Tedeschi, A., Bairey, O., Hillmen, P., Coutre, S. E., Devereux, S., Grosicki, S., McCarthy, H., Simpson, D., Offner, F., Moreno, C., Dai, S., Lal, I., Dean, J. P., & Kipps, T. J.
- Venue
- Leukemia
- Published
- 2019-10-18
- Volume
- 34
- Issue
- 3
- Pages
- 787-798
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2980937306
- Cited by
- 467
- References
- 31
- FWCI
- 30.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.